NOVO-B Novo Nordisk A/S

38.91USD265.15 DKK · CPH-2.32%Mkt Cap: 171.48B USDP/E: 10.25

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare D…

Institutional holders14 on file

Key Statistics

Company
Market Cap171.48B USD
Enterprise Value188.56B USD
Revenue (TTM)48.96B USD
Gross Profit36.73B USD
Net Income (TTM)15.03B USD
Revenue/Share11.04 USD
Last Price38.91 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees68.8K
CountryDK
SectorHealthcare
IndustryDrug Manufacturers - General
ISINDK0062498333
Valuation
P/E (Trailing)10.25
P/E (Forward)11.74
PEG4.17
EV/EBITDA7.08
EV/Revenue3.85
P/S3.50
P/B5.37
EPS (TTM)3.74 USD
EPS (Forward)3.34 USD
52W Range
32.9122% of range60.16
52W High60.16 USD
52W Low32.91 USD
Profitability
Gross Margin80.98%
Oper. Margin50.78%
EBITDA Margin54.41%
Profit Margin33.14%
ROE52.79%
ROA18.87%
ROIC33.61%
ROCE39.01%
Growth
Revenue Growth5.60%
Earnings Growth-15.80%
Cash Flow & Leverage
Operating CF17.48B USD
CapEx (TTM)13.22B USD
FCF Margin9.82%
FCF Yield2.80%
Net Debt12.93B USD
Net Debt/EBITDA0.49
Net Debt/FCF2.69
Balance Sheet
Debt/Equity0.67
Current Ratio0.84
Quick Ratio0.63
Book Value/Sh7.25 USD
Cash/Share1.54 USD
Dividends
Fwd Div Rate1.72 USD
Trail. Div Rate1.72 USD
Div. Yield4.31%
5Y Avg Yield1.51%
Payout Ratio45.90%
Ex-Div DateAug 14, 2026
Pay Date—
Splits
Last Split2:1
Split DateSep 13, 2023
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.01 USD
Upside (mean)+13.1%
Target Range32.43 USD – 65.74 USD
32.43+13.1% to mean65.74
# Analysts24
Ownership
Shares Out.3.33B
Float3.16B
Insiders5.27%
Institutions33.07%
Technical
SMA 5038.85 (+0.1%)
SMA 20040.99 (-5.1%)
Beta0.37
S&P 52W Chg12.08%
Avg Vol (30d)4.80M
Avg Vol (10d)5.83M
Technical Indicators
RSI (14)44.2
MACD-0.1739
MACD Signal-0.9273
MACD Hist.+0.7533
BB Upper42.00 USD
BB Middle39.59 USD
BB Lower37.19 USD
BB Width12.14%
ATR (14)1.177 USD
Vol Ratio (20d)0.88x

About Novo Nordisk (CPH: NOVO-B)

›

Novo Nordisk (CPH: NOVO-B) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 68,794 employees.

The shares were at 265.15 DKK on 19 November 2026, down 21.3% over 52 weeks. Its 52-week range is 224.25 DKK to 409.95 DKK: the price is 35.3% below the high and 18.2% above the low.

At a market capitalisation of 1.17T DKK, it trades at 10.2 times trailing earnings and 11.7 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 26.2, a discount of 61% for NOVO-B. It pays a dividend yielding 4.31% (it pays out 46% of its earnings), against a median of 2.42% among the dividend payers in that peer group.

Novo Nordisk reports return on equity of 52.8%, an operating margin of 50.8% and revenue up 5.6% year over year.

Its debt exceeds its cash by 88.13B DKK, a debt-to-equity ratio of 0.67. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 24 analysts cover the stock, with an average rating of Hold; their mean price target of 299.91 DKK is 13.1% above the current price. The next earnings report is expected on 3 February 2027.